Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
ALNY
ALNY
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ALNY News
Alnylam Pharmaceuticals Reports Mixed Q4 and 2025 Results
3d ago
NASDAQ.COM
Alnylam Pharmaceuticals Reports Strong 2025 Earnings Despite Stock Decline
3d ago
Fool
ALNYLAM PHARMACEUTICALS INC PROJECTS FY TOTAL NET PRODUCT REVENUE BETWEEN $4.9 BILLION AND $5.3 BILLION
3d ago
moomoo
Alnylam Pharmaceuticals Q4 Earnings Miss Expectations
3d ago
seekingalpha
Alnylam Pharmaceuticals to Announce Q4 Earnings on February 12
4d ago
seekingalpha
Alnylam Pharmaceuticals Q4 2025 Earnings Outlook
Jan 28 2026
Fool
Marvell Technology and Others May Join S&P 500
Jan 16 2026
CNBC
Rare Disease Biotechs Show Strong 2025 Performance with Cashflow and R&D Expansion
Jan 14 2026
Yahoo Finance
S&P 500 Hits Record High as Data Storage Stocks Lead Gains
Jan 13 2026
NASDAQ.COM
Trump Pressures Fed, Credit Card Stocks Slide Amid Legal Threats
Jan 12 2026
NASDAQ.COM
Trump Pressures Fed, Stock Markets Dip Slightly Amid Concerns
Jan 12 2026
NASDAQ.COM
Alnylam Pharmaceuticals Unveils 'Alnylam 2030' Strategy Targeting 25% Annual Revenue Growth
Jan 12 2026
Benzinga
Gold and Silver Hit Record Highs as Investors Reassess Fed Independence Amid Political Tensions
Jan 12 2026
Benzinga
Alnylam Pharmaceuticals Down 8.1%, Worst Performer on Nasdaq 100
Jan 12 2026
NASDAQ.COM
Alnylam Unveils 'Alnylam 2030' Strategy Targeting 25% CAGR Through 2030
Jan 12 2026
NASDAQ.COM
Alnylam Unveils 'Alnylam 2030' Strategy, Projects $4.9B to $5.3B Revenue for 2026
Jan 11 2026
Businesswire
Show More News
